Covered recipient · General Payments record
SUSAN E DOCK
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2020–2024
$1,542.68
- Reported across 91 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $276.68 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $93.33 | 6 |
| Phathom Pharmaceuticals, Inc. | $39.33 | 2 |
| Lilly USA, LLC | $34.64 | 2 |
| Acerta Pharma LLC | $32.07 | 2 |
| Amgen Inc. | $28.20 | 2 |
| Astellas Pharma US Inc | $21.42 | 1 |
| PFIZER INC. | $14.06 | 1 |
| ABBVIE INC. | $13.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.63 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107030555 | CMS |
| Amgen Inc. | $14.48 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117240288 | CMS |
| Amgen Inc. | $13.72 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117240290 | CMS |
| Astellas Pharma US Inc | $21.42 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139489320 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.87 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104262675 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.20 | 08/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105779936 | CMS |
| Lilly USA, LLC | $13.45 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135869061 | CMS |
| Lilly USA, LLC | $21.19 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135948828 | CMS |
| Novo Nordisk Inc | $17.50 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100491669 | CMS |
| Novo Nordisk Inc | $15.78 | 04/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100269876 | CMS |
| Novo Nordisk Inc | $13.84 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100506285 | CMS |
| Novo Nordisk Inc | $14.92 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100519891 | CMS |
| Novo Nordisk Inc | $16.52 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100422834 | CMS |
| Novo Nordisk Inc | $14.77 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100591020 | CMS |
| PFIZER INC. | $14.06 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131787761 | CMS |
| Phathom Pharmaceuticals, Inc. | $17.71 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151161010 | CMS |
| Phathom Pharmaceuticals, Inc. | $21.62 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151161012 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.